Redwood City, Calif., February 12, 2024 – Nuvig Therapeutics, Inc., (“Nuvig” or the “Company”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease. Nuvig also announced…
Physician and biopharmaceutical leadership executive with extensive experience in novel drug development, operations management, and team building Redwood City, Calif., October 4, 2023 – Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer. Dr. Glicklich has…
Redwood City, Calif., May 11, 2022 – Nuvig Therapeutics, Inc., announced today the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function. To support this mission, the company has closed a $47 million Series A financing, led by Novo Holdings A/S…